Galena Biopharma Inc (NASDAQ:GALE) Rallies On Breast Cancer Vac Neuvax


Dallas, Texas 12/03/2013 (Financialstrend) – Galena Biopharma Inc (NASDAQ:GALE) shares were found to be soaring high on the stock market, backed by news of the successful results for its path-breaking vaccine for breast-cancer: NeuVax. Additionally news about launch of ‘Abstral’ in the U.S. markets too is expected to pay rich dividends. With several high-quality products in the pipeline, Galena is expected to maximize funds for further development as soon as Abstral is established in the North American continent.

NeuVax Galena’s gold mine

Investors in the pharmaceutical industry are attracted to Galena Biopharma Inc, for its vaccine NeuVax. The product is focused on providing treatment for breast cancer. It has already been successful in the Phase 2 trails when used with another drug for breast cancer- Herceptin. It is currently in the Phase 3 trials for the same.

Known earlier as RXi Pharmaceuticals Corporation, Galena Biopharma Inc (NASDAQ:GALE) has been focused on developing commercial drug solutions for medical ailments which need drugs. It has effectively used targeted biotherapeutics to build its drugs.

Currently, the drugs for treating cancer which Galena currently has in its labs use a peptide-base. The products developed are therapeutic as well as incorporating immunological solutions. The candidate that Gelana is currently using is NeuVaxTM (E75) to stabilize a cure for most tumors and especially breast cancer.

Why is NeuVax a wonder therapy?

The most common treatment for breast cancer has been trastuzumab (Herceptin; Genentech/Roche), which sometimes cannot be used. NeuVax on the other hand being a peptide-based drug can easily be used to prevent the reoccurrence of breast cancer,when it is yet in the intermediate and lower levels.

Now, that NeuVax phase 2 trial has been successful in ensuring DFS (Disease-free-survival), it is expected to become the most sought after preventive cancer drug product.

Incidentally, Galena Biopharma Inc (NASDAQ:GALE) shares are soaring at 7.59% higher than average prices, trading between $4.04 -$4.52.